PSMA-Specific Radiophamaceuticals for Imaging and Therapy of Prostate Cancer
https://doi.org/10.56304/S2079562922030526
Abstract
Molecular changes associated with prostate cancer result in increased expression of prostate specific membrane antigen (PSMA), which is a favorable target for imaging and therapy with radiopharmaceuticals. In this review the data on the most effective and clinically relevant PSMA-specific radiopharmaceuticals for diagnosis and therapy of prostate cancer were summarized. The advantages and drawbacks of ligands based on monoclonal antibodies and their fragments, as well as low molecular weight PSMA inhibitors were discussed.
About the Authors
V. K. Tishchenko
Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 249031
V. M. Petriev
Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 249031,
Moscow, 115409
O. P. Vlasova
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 249036
V. V. Krylov
Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 249031
P. V. Shegai
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 249036
S. A. Ivanov
Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation;
Рeoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 24903,
Moscow, 117198
A. D. Kaprin
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation;
Рeoples’ Friendship University of Russia (RUDN University)
Russian Federation
Russian Federation
Obninsk, Kaluga oblast, 249036,
Moscow, 117198
References
1. Global Cancer Observatory. https://gco.iarc.fr/.
2. Czerwińska M., Bilewicz A., Kruszewski M., et al. // Molecules. 2020. V. 25 (7). P. 1743.
3. de Galiza Barbosa F., Queiroz M.A., Nunes R.F., et al. // Cancer Imaging. 2020. V. 20. P. 23.
4. Rodriguez-Fraile M., Alonso P.T., Rosales J.J., et al. // Rev. Esp. Med. Nucl. Imagen. Mol. (Engl. Ed.). 2022. V. 41 (2). P. 126.
5. Manyak M.J. // Expert. Rev. Anticancer Ther. 2008. V. 8 (2). P. 175.
6. Pandit-Taskar N., O’Donoghue J.A., Morris M.J., et al. // J. Nucl. Med. 2008. V. 49 (7). P. 1066.
7. Pandit-Taskar N., O’Donoghue J.A., Beylergil V., et al. // Eur. J. Nucl. Med. Mol. Imaging. 2014. V. 41 (11). P. 2093.
8. Pandit-Taskar N., O’Donoghue J.A., Durack J.C., et al. // Clin. Cancer Res. 2015. V. 21 (23). P. 5277.
9. Milowsky M.I., Nanus D.M., Kostakoglu L., et al. // J. Clin. Oncol. 2004. V. 22. P. 2522.
10. Vallabhajosula S., Nikolopoulou A., Jhanwar Y.S., et al. // Curr. Radiopharm. 2016. V. 9 (1). P. 44.
11. Tagawa S.T., Vallabhajosula S., Christos P.J., et al. // Cancer. 2019. V. 125 (5). P. 2561.
12. Niaz M.J., Batra J.S., Walsh R.D., et al. // Oncologist. 2020. V. 25 (6). P. 477.
13. Nelson B.J.B., Andersson J.D., Wuest F. // Pharmaceutics. 2021. V. 13 (1). P. 49.
14. Tagawa S.T., Osborne J., Niaz M.J., et al. // J. Clin. Oncol. 2020. V. 38. P. 114.
15. Rondon A., Rouanet J., Degoul F. // Cancers (Basel). 2021. V. 13 (21). P. 5570.
16. Pandit-Taskar N., O’Donoghue J.A., Ruan S., et al. // J. Nucl. Med. 2016. V. 57 (12). P. 1858.
17. Maresca K.P., Hillier S.M., Femia F.J., et al. // J. Med. Chem. 2009. V. 52 (2). P. 347.
18. Duatti A. // Nucl. Med. Biol. 2021. V. 92. P. 202.
19. Wester H.J., Schottelius M. // Semin. Nucl. Med. 2019. V. 49. P. 302.
20. Robu S., Schottelius M., Eiber M., et al. // J. Nucl. Med. 2017. V. 58 (2). P. 235.
21. Eder M., Schäfer M., Bauder-Wüst U., et al. // Bioconjug. Chem. 2012. V. 23 (4). P. 688.
22. Kiess A.P., Banerjee S.R., Mease R.C., et al. // Q. J. Nucl. Med. Mol. Imaging. 2015. V. 59 (3). P. 241.
23. Fendler W.P., Calais J., Eiber M., et al. // JAMA Oncol. 2019. V. 5 (6). P. 856.
24. Afshar-Oromieh A., Holland-Letz T., Giesel F.L., et al. // Eur. J. Nucl. Med. Mol. Imaging. 2017. V. 44. P. 1258.
25. Liu A., Han J., Nakano A., et al. // Chirality. 2022. V. 34 (1). P. 86.
26. Piron S., Verhoeven J., Vanhove C., et al. // Nucl. Med. Biol. 2022. V. 106−107. P. 29.
27. Morris M.J., Rowe S.P., Gorin M.A., et al. // Clin. Cancer Res. 2021. V. 27 (13). P. 3674.
28. Pienta K.J., Gorin M.A., Rowe S.P., et al. // J. Urol. 2021. V. 206. P. 52.
29. Watabe T., Uemura M., Soeda F., et al. // Ann. Nucl. Med. 2021. V. 35. P. 523.
30. Rauscher I., Krönke M., König M., et al. // J. Nucl. Med. 2020. V. 61 (1). P. 51.
31. Zechmann C.M., Afshar-Oromieh A., Armor T., et al. // Eur. J. Nucl. Med. Mol. Imaging. 2014. V. 41. P. 1280.
32. Ma J., Li L., Liao T., et al. // Front. Oncol. 2022. V. 12. P. 796657.
Review
For citations:
Tishchenko V.K., Petriev V.M., Vlasova O.P., Krylov V.V., Shegai P.V., Ivanov S.A., Kaprin A.D. PSMA-Specific Radiophamaceuticals for Imaging and Therapy of Prostate Cancer. Nuclear Physics and Engineering. 2022;13(6):611-616. (In Russ.) https://doi.org/10.56304/S2079562922030526
Views:
51
Email this article 